Indications |
Intravenous Ewing's sarcoma Adult: 15 mcg/kg/day or 400-600 mcg/m2 BSA/day for 5 days. Child: >6 mth: 15 mcg/kg/day or 400-600 mcg/m2 BSA/day. To be given for 5 days per 2-wk cycle. Intravenous Wilm's tumour Adult: 15 mcg/kg/day or 400-600 mcg/m2 BSA/day for 5 days. Child: >6 mth: 15 mcg/kg/day or 400-600 mcg/m2 BSA/day. To be given for 5 days per 2-wk cycle. Intravenous Childhood rhabdomyosarcoma Adult: 15 mcg/kg/day or 400-600 mcg/m2 BSA/day for 5 days. Child: >6 mth: 15 mcg/kg/day or 400-600 mcg/m2 BSA/day. To be given for 5 days per 2-wk cycle. Intravenous Gestational trophoblastic tumours Adult: 12 mcg/kg/day for 5 days as a single agent or 500 mcg/day on days 1 and 2 of combination regimens. Intravenous Metastatic nonseminomatous testicular cancer Adult: 1 mg/m2 on day 1 of combination regimens. Special Populations: Adult and children: dose intensity should not exceed 15 mcg/kg/day or 400-600 mcg/m2/day for 5 days /2-week cycle. Lower doses may be used when combined with chemotherapy or radiotherapy. Reconstitution: Reconstitute with sterile water for inj without preservatives under aseptic conditions because preservatives may cause precipitation. Incompatibility: Y-site incompatibility: Filgrastim. |
Contraindications |
Infection with chicken pox or herpes zoster; hypersensitivity; infants <12 mth. Lactation. |
Warnings / Precautions |
Admin drug with care to avoid extravsasation. GI toxicity and bone marrow suppression has been reported when given with x-ray therapy. Increased risk of hepatomegaly and elevated SGOT levels when administering within 2 mth of irradiation for the treatment of right-sided Wilms' tumor. Discontinue drug if stomatitis, diarrhoea or severe haematopoietic depression results, until patient recovers. Monitor renal, hepatic and bone marrow functions regularly. Pregnancy. |
Adverse Reactions |
Cheilitis, dysphagia, oesophagitis, ulcerative stomatitis, pharyngitis; anorexia, nausea, vomiting, abdominal pain, diarrhoea, GI tract ulceration; liver toxicity including ascites, hepatomegaly, hepatitis, LFT abnormalities; anaemia, agranulocytosis, leukopenia, thrombocytopenia, pancytopenia, reticulopenia, alopoecia; skin eruptions, acne, flare-up of erythema or increased pigmentation of previously irradiated skin. If extravasation occurs during IV use, it leads to severe damage of soft tissues. Malaise, fatigue, lethargy, fever, myalgia, proctitis and hypocalcaemia. Potentially Fatal: Veno-occlusive disease (primarily hepatic) may result in fatality especially in children <48 mth. |
Overdose Reactions |
Nausea, vomiting, diarrhoea, mucositis, GI ulceration, skin disorders (e.g. exanthema, desquamation and epidermolysis), severe haematopoietic depression, veno-occlusive disease, acute renal failure and death. Treatment of toxicity is mainly symptomatic and supportive. Monitor skin and mucous membrane integrity, renal, hepatic and bone marrow functions frequently. |
Lab Interactions |
Dactinomycin may interfere with bioassay procedures for the determination of antibacterial drug levels. |
Mechanism of Actions |
Dactinomycin binds to the guanine portion of DNA forming a complex which interferes with DNA and RNA synthesis as well as protein synthesis. It may also enhance the cytotoxic effects of radiotherapy. Distribution: Rapidly distributed with high concentrations in bone marrow and nucleated cells. Metabolism: Minimal metabolism. Excretion: Slowly excreted in urine and bile. Plasma half-life: about 36 hr. |
Storage Conditions |
Intravenous: Store at 25°C. |
ATC Classification |
L01DA01 - dactinomycin ; Belongs to the class of cytotoxic antibiotics, actinomycines. Used in the treatment of cancer. |
Storage |
Intravenous: Store at 25°C. |
Available As |
|
Dactinomycin (Actinomycin D)
Post Review about Dactinomycin (Actinomycin D) Click here to cancel reply.
Dactinomycin (Actinomycin D) Containing Brands
Dactinomycin (Actinomycin D) is used in following diseases
Drug - Drug Interactions of Dactinomycin (Actinomycin D)
Latest News
- FDA approves Ruconest for treatment of hereditary angioedema
- FDA recommend against aspirin to prevent First Heart Attacks
- FDA approves Pomalyst (pomalidomide) for advanced multiple myeloma
- FDA approves three new drug treatments for type 2 diabetes
- Long-term consequences of vaginal delivery on the pelvic floor
No comments yet.